OncoMatch/Clinical Trials/NCT05551208
Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi
Is NCT05551208 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies fluzopanib and bevacizumab for ovarian cancer.
Treatment: fluzopanib and bevacizumab — There are more and more PARPi(PARP inhibitors) resistance for ovarian cancer patients after previous use of PARP inhibitors. Basic studies have found that there is synergistic effect of bevacizumab combined with PARPi. Therefore we designed the study to include 42 ovarian cancer patients who had PARPi for at least half a year and then relapsed (platinum-sensitive, previously 1-3 lines of chemotherapy). After getting complete remission or partial remission with chemotherapy containing platinum and bevacizumab, fluzopanib and bevacizumab were used for maintenance treatment. The progression-free survival, ORR, DCR, DoR, and safety were evaluated based on RECIST V1.1.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — after primary cytoreductive surgery
had received platinum-based regimens for at least 1-3 lines after primary cytoreductive surgery
Must have received: PARP inhibitor
PSROC Previously Treated With PARPi
Cannot have received: VEGF inhibitor (bevacizumab)
Exception: allowed if >6 months since last use
Had used bevacizumab within 6 months of enrollment
Lab requirements
Blood counts
CBC Hb≥90g/L, ANC≥1.5×10^9/L, PLT≥100×10^9/L
Kidney function
Serum creatinine≤1.5×ULN
Liver function
Serum ALT≤3×UL, AST≤3×ULN
CBC Hb≥90g/L, ANC≥1.5×10^9/L, PLT≥100×10^9/L, Serum ALT≤3×UL, AST≤3×ULN#Serum creatinine≤1.5×ULN#
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify